BACON (Bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients

R. B. Livingston, W. H. Fee, Lawrence Einhorn, M. A. Burgess, E. J. Freireich, J. A. Gottlieb, M. O. Farber

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Fifty patients with inoperable squamous carcinoma of the lung, 38 with extensive, and 12 with limited disease, were treated with BACON. Tumor regression > 50% was observed in 17 patients (45%) with extensive, and four patients (33%) with limited disease. Stabilization of disease for ≥ 8 weeks was seen in four extensive and eight limited patients, and had the same prognostic importance with regard to survival as response: in extensive disease, responding and stable patients had median survival (MST) of 26 weeks from start of therapy, while MST for non responders was 9 weeks. MST in limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for supportive care alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks, rather than every 4 weeks.

Original languageEnglish (US)
Pages (from-to)1237-1242
Number of pages6
JournalCancer
Volume37
Issue number3
DOIs
StatePublished - 1976

Fingerprint

Lomustine
Mechlorethamine
Bleomycin
Vincristine
Doxorubicin
Lung Neoplasms
Survival
Survival Analysis
Squamous Cell Carcinoma
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

BACON (Bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients. / Livingston, R. B.; Fee, W. H.; Einhorn, Lawrence; Burgess, M. A.; Freireich, E. J.; Gottlieb, J. A.; Farber, M. O.

In: Cancer, Vol. 37, No. 3, 1976, p. 1237-1242.

Research output: Contribution to journalArticle

Livingston, R. B. ; Fee, W. H. ; Einhorn, Lawrence ; Burgess, M. A. ; Freireich, E. J. ; Gottlieb, J. A. ; Farber, M. O. / BACON (Bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients. In: Cancer. 1976 ; Vol. 37, No. 3. pp. 1237-1242.
@article{19f0f280fd574fcdbd7feca39179f09c,
title = "BACON (Bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients",
abstract = "Fifty patients with inoperable squamous carcinoma of the lung, 38 with extensive, and 12 with limited disease, were treated with BACON. Tumor regression > 50{\%} was observed in 17 patients (45{\%}) with extensive, and four patients (33{\%}) with limited disease. Stabilization of disease for ≥ 8 weeks was seen in four extensive and eight limited patients, and had the same prognostic importance with regard to survival as response: in extensive disease, responding and stable patients had median survival (MST) of 26 weeks from start of therapy, while MST for non responders was 9 weeks. MST in limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for supportive care alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks, rather than every 4 weeks.",
author = "Livingston, {R. B.} and Fee, {W. H.} and Lawrence Einhorn and Burgess, {M. A.} and Freireich, {E. J.} and Gottlieb, {J. A.} and Farber, {M. O.}",
year = "1976",
doi = "10.1002/1097-0142(197603)37:3<1237::AID-CNCR2820370302>3.0.CO;2-Z",
language = "English (US)",
volume = "37",
pages = "1237--1242",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - BACON (Bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients

AU - Livingston, R. B.

AU - Fee, W. H.

AU - Einhorn, Lawrence

AU - Burgess, M. A.

AU - Freireich, E. J.

AU - Gottlieb, J. A.

AU - Farber, M. O.

PY - 1976

Y1 - 1976

N2 - Fifty patients with inoperable squamous carcinoma of the lung, 38 with extensive, and 12 with limited disease, were treated with BACON. Tumor regression > 50% was observed in 17 patients (45%) with extensive, and four patients (33%) with limited disease. Stabilization of disease for ≥ 8 weeks was seen in four extensive and eight limited patients, and had the same prognostic importance with regard to survival as response: in extensive disease, responding and stable patients had median survival (MST) of 26 weeks from start of therapy, while MST for non responders was 9 weeks. MST in limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for supportive care alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks, rather than every 4 weeks.

AB - Fifty patients with inoperable squamous carcinoma of the lung, 38 with extensive, and 12 with limited disease, were treated with BACON. Tumor regression > 50% was observed in 17 patients (45%) with extensive, and four patients (33%) with limited disease. Stabilization of disease for ≥ 8 weeks was seen in four extensive and eight limited patients, and had the same prognostic importance with regard to survival as response: in extensive disease, responding and stable patients had median survival (MST) of 26 weeks from start of therapy, while MST for non responders was 9 weeks. MST in limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for supportive care alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks, rather than every 4 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0017250330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017250330&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197603)37:3<1237::AID-CNCR2820370302>3.0.CO;2-Z

DO - 10.1002/1097-0142(197603)37:3<1237::AID-CNCR2820370302>3.0.CO;2-Z

M3 - Article

C2 - 56980

AN - SCOPUS:0017250330

VL - 37

SP - 1237

EP - 1242

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -